{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:24Z","timestamp":1777934604636,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cases of osteonecrosis of the jaw have been reported by dental surgeons to the pharmacovigilance center in Rennes, France, occurring among patients treated with palbociclib, a cyclin-dependent kinase 4\/6 inhibitor. Although this event was not expected with the drug, a safety signal was raised. Describing a local case series, the aim of our study was to identify specific patterns that might suggest a triggering role for these drugs, and to discuss pathophysiological hypotheses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A retrospective case series of patients exposed to cyclin-dependent kinase 4\/6 inhibitors between 2016 and 2020 with a diagnosis of osteonecrosis of the jaw at the Rennes Dental Care Center was analyzed. The descriptive analysis was conducted on patient demographics, breast cancer characteristics, osteonecrosis of the jaw, biological data, and exposure to cyclin-dependent kinase 4\/6 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified eight cases, most of them at stages 0\u20131 (62.5%). Four patients were still exposed to palbociclib at the time of diagnosis and four had discontinued the treatment before the diagnosis. Chronological imputability could not be excluded given the drug\u2019s half-life and the variable intervals of dental monitoring from one patient to another. All patients had at least one dental osteonecrosis risk factor (including dental extraction, dentures, and denosumab exposure at the time of diagnosis). Neutropenia and mucositis were not systematically reported at the time of diagnosis. The anatomopathological characteristics were nonspecific.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We did not identify a specific pattern that could suggest a triggering role of palbociclib in the development of ONJ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231165434","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T03:27:36Z","timestamp":1679455656000},"page":"1990-1997","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Osteonecrosis of the jaw under palbociclib: A case series description"],"prefix":"10.1177","volume":"29","author":[{"given":"Chabnam","family":"Yosofi","sequence":"first","affiliation":[{"name":"Regional Center of Pharmacovigilance, Pharmacoepidemiology and Drug Information \u2013 CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Cairon-Lejeune","sequence":"additional","affiliation":[{"name":"Dental Care Center, CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lefeuvre-Plesse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Eug\u00e8ne Marquis Cancer Center, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[{"name":"Regional Center of Pharmacovigilance, Pharmacoepidemiology and Drug Information \u2013 CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Briet","sequence":"additional","affiliation":[{"name":"Regional Center of Pharmacovigilance, Pharmacoepidemiology and Drug Information \u2013 CHRU Angers, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol\u00e8ne-Florence","family":"Kammerer-Jacquet","sequence":"additional","affiliation":[{"name":"Department of Pathology, CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Triquet","sequence":"additional","affiliation":[{"name":"Regional Center of Pharmacovigilance, Pharmacoepidemiology and Drug Information \u2013 CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-9107","authenticated-orcid":false,"given":"Lucie-Marie","family":"Scailteux","sequence":"additional","affiliation":[{"name":"Regional Center of Pharmacovigilance, Pharmacoepidemiology and Drug Information \u2013 CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"bibr1-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4614"},{"key":"bibr2-10781552231165434","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1169-8330(17)30344-7","volume":"84","author":"Cl\u00e9zardin P","year":"2017","journal-title":"Rev Rhum Monogr"},{"key":"bibr3-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1051\/mbcb\/2021035"},{"key":"bibr4-10781552231165434","unstructured":"European Medicines Agency. Ibrance: EPAR - Product information, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ibrance-epar-product-information_en.pdf  (accessed 21 January 2022)."},{"key":"bibr5-10781552231165434","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). Compte rendu du comit\u00e9 scientifique permanent de surveillance et pharmacovigilance - S\u00e9ance du 28 janvier 2020, https:\/\/archiveansm.integra.fr\/var\/ansm_site\/storage\/original\/application\/e121b171bff4718399c01bc6f06a3233.pdf (accessed 21 January 2022)."},{"key":"bibr6-10781552231165434","unstructured":"European Medicines Agency. Ibrance: EPAR - Public Assessment Report - September 2016 (#EMA\/652627\/2016), https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ibrance-epar-public-assessment-report_en.pdf (accessed 26 September 2021)."},{"key":"bibr7-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0142"},{"key":"bibr8-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.09.004"},{"key":"bibr9-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1111\/clr.12556"},{"key":"bibr10-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2018.09.008"},{"key":"bibr11-10781552231165434","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17249509"},{"key":"bibr12-10781552231165434","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph181910145"},{"key":"bibr13-10781552231165434","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph181910143"},{"key":"bibr14-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"bibr15-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8768162"},{"key":"bibr16-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-018-0474-4"},{"key":"bibr17-10781552231165434","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.606043"},{"key":"bibr18-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgz009"},{"key":"bibr19-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-016-0318-z"},{"key":"bibr20-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201901819RR"},{"key":"bibr21-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.06.007"},{"issue":"1","key":"bibr22-10781552231165434","volume":"25","author":"Eguia A","year":"2020","journal-title":"Med Oral Patol Oral Cirugia Bucal"},{"key":"bibr23-10781552231165434","unstructured":"UK Chemotherapy Board. Medication-related osteonecrosis of the jaw: guidance for the oncology multidisciplinary team, 2019, https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/medication-related-osteonecrosis-jaw-guidance-oncology-multidisciplinary-team"},{"key":"bibr24-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1177\/0022034515572021"},{"key":"bibr25-10781552231165434","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194925"},{"key":"bibr26-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2018.03.003"},{"key":"bibr27-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4701"},{"key":"bibr28-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"bibr29-10781552231165434","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212579"},{"key":"bibr30-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0019"},{"key":"bibr31-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0097"},{"key":"bibr32-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.05.016"},{"key":"bibr33-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0721-5"},{"key":"bibr34-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918793326"},{"key":"bibr35-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.017"},{"key":"bibr36-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01263-0"},{"key":"bibr37-10781552231165434","first-page":"17","author":"Czarny K","year":"2020","journal-title":"EMC-M\u00e9decine Buccale"},{"key":"bibr38-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04925-8"},{"key":"bibr39-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/j.adaj.2017.08.046"},{"key":"bibr40-10781552231165434","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"bibr41-10781552231165434","unstructured":"Beaudouin S. Incidence de l\u2019ost\u00e9eon\u00e9crose des maxillaires de patients sous Xgeva (d\u00e9nosumab 120 mg): \u00e9tude de cohorte r\u00e9trospective. Practice thesis, Universit\u00e9 de Rennes 1, 2020."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231165434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231165434","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231165434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:08Z","timestamp":1777688888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231165434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/10781552231165434"],"URL":"https:\/\/doi.org\/10.1177\/10781552231165434","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}